FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Sleep Disorders topics
Sleep Disorder
Sleep Disorders
Narcolepsy
Schizophrenia
Antagonist
Pyrazole Derivatives
Movement Disorder
Movement Disorders
Eating Disorder
Eating Disorders
Neurological
Pharmaceutically Acceptable Salt
Intracranial
Opiate Withdrawal
Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Sleep Disorders patents



      
           
This page is updated frequently with new Sleep Disorders-related patents. Subscribe to the Sleep Disorders RSS feed to automatically get the update: related Sleep RSS feeds.

Subscribe to updates on this page: Sleep Disorders RSS RSS

Date/App# patent app List of recent Sleep Disorders-related patents
04/17/14
20140107084
 Ultra low dose doxepin and methods of using the same to treat sleep disorders patent thumbnailnew patent Ultra low dose doxepin and methods of using the same to treat sleep disorders
The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .
03/06/14
20140066504
 Analogs and prodrugs of bumetanide; compositions and methods of use patent thumbnailAnalogs and prodrugs of bumetanide; compositions and methods of use
Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described.
03/06/14
20140066412
 Heteroaryl substituted urea modulators of fatty acid amide hydrolase patent thumbnailHeteroaryl substituted urea modulators of fatty acid amide hydrolase
Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..
02/20/14
20140051750
 Low-dose doxepin for treatment of sleep disorders in elderly patients patent thumbnailLow-dose doxepin for treatment of sleep disorders in elderly patients
Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.
02/20/14
20140050783
 Methods and compositions for sleep disorders and other disorders patent thumbnailMethods and compositions for sleep disorders and other disorders
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or parkinson's disease or any combinations..
02/13/14
20140045800
 Tetracyclic inhibitors of fatty acid amide hydrolase patent thumbnailTetracyclic inhibitors of fatty acid amide hydrolase
Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis)..
02/13/14
20140045755
 Methods for treating sleep disorders by cholecystokinin (cck) receptor b antagonists patent thumbnailMethods for treating sleep disorders by cholecystokinin (cck) receptor b antagonists
The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (cck) receptor antagonists..
02/06/14
20140038951
 Pde10 inhibitors and related compositions and methods patent thumbnailPde10 inhibitors and related compositions and methods
Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.
01/09/14
20140011775
 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists patent thumbnailArylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
01/02/14
20140005182
 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators patent thumbnailAryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
12/12/13
20130331610
Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.
12/12/13
20130331571
Glycine transporter-inhibiting substances
The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .
12/12/13
20130331401
Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.
12/12/13
20130331396
Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
Certain piperazinyl and piperidinyl urea compounds are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity.
12/05/13
20130324788
Method and apparatus for treatment of sleep disorders
A system for therapy may include a mask (200) for a patient having a frame, cushion, forehead support and a light (100). The mask is connectable to a respiratory treatment apparatus, such as a flow generator, to receive breathable gas for a respiratory therapy.
11/28/13
20130312768
Apparatus and methods for the treatment of sleep apnea
A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element.
11/07/13
20130296993
Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.
11/07/13
20130296413
N-desmethyl-doxepin and methods of using the same to treat sleep disorders
Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .
10/10/13
20130267595
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.
09/19/13
20130245022
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..
08/22/13
20130217729
Piperidine sulphonamide derivatives
Wherein ar1, ar2, r1, r2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula i are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases..
08/22/13
20130217700
Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).
08/15/13
20130210856
Compositions and methods for treating sleep disorders
The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a metal oxide, and a borate salt.
08/01/13
20130196994
Pde10 inhibitors and related compositions and methods
Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.
07/18/13
20130184298
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
The present invention is directed to dihydrobenzoquinazilinone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
07/18/13
20130184286
Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors
This invention is related to the alkyl-piperazine-phenyl 4 (3h)-quinazolinones general formula (i) compounds, pharmacologically active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..
06/13/13
20130150434
Methods of using low-dose doxepin for the improvement of sleep
Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.. .
06/06/13
20130143965
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.
06/06/13
20130143912
Sublingual zolpidem formulations
The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the ph of saliva to a ph greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form.
06/06/13
20130143868
Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of dopa decarboxylase inhibiting compounds, catechol-o-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.
05/30/13
20130137865
Heteroaryl-pyrazole derivative
A compound represented by formula [i] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group ii metabotropic glutamate (mglu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.. .
05/16/13
20130123500
Ethinyl-pyrazole derivative
Provided is a novel compound represented by formula [i] or a pharmaceutically acceptable salt thereof having antagonistic activity against group ii metabolism-type glutamic acid (m-glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like..
05/16/13
20130122092
Three-phase controlled-release tablet comprising melatonin and process of preparation
The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders..
05/16/13
20130118504
System and method for delivering a therapy and sensing a biological activity in the mouth
Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (tst) and tongue position sensor (tse) is provided, according to certain aspects.
05/09/13
20130116272
Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
05/02/13
20130109686
Isoindolone m1 receptor positive allosteric modulators
The present invention is directed to isoindolone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
04/25/13
20130102928
System and method for managing sleep disorders
The present invention provides a method for managing a patient having a sleep disorder, e.g. Sleep apnea, snoring, sleep bruxism, upper airway resistance syndrome, etc.
04/25/13
20130102658
Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
The invention relates to use of the cis-(z) isomer or isomeric mixtures containing specified ratios of the cis-(z) and trans-(e) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders. .
04/25/13
20130102599
Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
04/18/13
20130096188
Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
The invention relates to use of the trans-(e) isomer or isomeric mixtures containing specified ratios of the trans-(e) and cis-(z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders. .
04/11/13
20130090352
Tetrahydroquinoline amide m1 receptor positive allosteric modulators
The present invention is directed to tetrahydroquinoline amide compounds of formula (i) (formula should be inserted here) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
03/28/13
20130078304
Controlled release formulation for treating sleep disorders
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein zaleplon or a pharmaceutically acceptable salt thereof and zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of zolpidem or a pharmaceutically acceptable salt thereof.. .
03/14/13
20130064804
Bio-replenishment (biorep) for improving sleep architecture
Methods to prepare a bio-replenishment (biorep) with specific combinations of s-adenosylmethionine (same), lactoferrin (lf) and ribonuclease (rnase) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (nrem) and rapid eye movement (rem) sleep cycles are disclosed.
03/07/13
20130059860
Naphthalene carboxamide m1 receptor positive allosteric modulators
The present invention is directed to naphthalene carboxamide compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
02/28/13
20130053398
Modulators of fatty acid amide hydrolase
4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a faah modulator. 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
02/21/13
20130042876
System and method for delivering a therapy and sensing a biological activity in the mouth
Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (tst) and tongue position sensor (tse) is provided, according to certain aspects.
02/14/13
20130040959
Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
The present invention is directed to novel 3-oxo-2,3-dihydropyrazolo[4,3-c]quinolizine derived compounds of generic formula (i) or a pharmaceutically acceptable salt thereof, which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
01/31/13
20130029291
Dual use exercise whitener appliance
A jaw-joint protective device is provided for whitening and brightening a wearer's teeth while protecting the teeth, tongue, lips, jaw, and other delicate structures of the vital cranial triad (vct) from injury and/or for supporting the condyle of the temporomandibular joint (tmj) in a relatively fixed (stable) position thereby stabilizing the jaw and the vct during head contact activity, exercise, physical rehabilitation, c-force acceleration, teeth grinding disorders and sleep apnea and or permit the components of a vct disorder to be realigned for proper healing. This device is an over-the-counter purchased, boil and bite device for whitening at least one tooth while protecting the jaw-joint, providing maxillary and mandibular teeth seats for protection of the mouth and/or healing of the vct.
01/24/13
20130021158
System and method of detecting sleep disorders
An apparatus for detecting sleep disorders, such as obstructive sleep apnea, includes a housing insertable into an ear canal of a subject. A sensor disposed within the housing measures a position of the subject's head relative to an axis of gravity.
01/17/13
20130018090
Low-dose doxepin for treatment of sleep disorders in elderly patients
Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.


Popular terms: [SEARCH]

Sleep Disorders topics: Sleep Disorder, Sleep Disorders, Narcolepsy, Schizophrenia, Antagonist, Pyrazole Derivatives, Movement Disorder, Movement Disorders, Eating Disorder, Eating Disorders, Neurological, Pharmaceutically Acceptable Salt, Intracranial, Opiate Withdrawal, Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Sleep Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sleep Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.1999

2547

2 - 1 - 50